According to the current analysis of Reports and Data, the global Automated Insulin Delivery Systems Market was valued at USD 4.91 billion in 2019 and is expected to reach USD 7.81 billion by the year 2027 at a CAGR of 6.0%. The Automated Insulin Delivery Systems (AID) market is majorly driven due to the increasing prevalence of diabetes across the globe. Diabetes is a chronic metabolic disease characterized by increased blood glucose levels or blood sugar, which is likely to lead to heart disorders, damage to blood vessels, eyes, kidneys, and nerves. In 2019, nearly 463 million adults from 20 to 79 years old had diabetes and is estimated to rise to about 700 million by 2045 globally, according to the International Diabetes Federation.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3453
The continuous growth in the target population has promoted a rise in technological advances in the field emerging tremendous future opportunity for Automated Insulin Delivery Systems. For instance, one of the leading players in the industry Bigfoot Biomedical is engaged in developing its advanced AID system Autonomy with the use of a screenless pump, a smartphone app, and the FreeStyle Libre CGM; which is estimated to be launched by 2023. Increasing technological developments, favorable reimbursement policies, and increasing awareness programs are estimated to support the market growth. Furthermore, rising diabetic population worldwide has attracted research investments from private and public organizations, towards diabetes management. For instance, the NIH has invested in collaboration with four institution to support development of closed-loop insulin delivery technology or Automated Insulin Delivery Systems for pregnant women with type 1 diabetes in 2019.
Further key findings from the report suggest:
- To capture significant clientele, companies are engaged in developing advanced automated products with enhanced efficiency and ease of use. For instance, in June 2020, Medtronic received the CE-Mark for its MiniMed 780G. The device automatically adjust basal insulin rates after every five minutes and is suitable for diabetic of 7- 80 year old
- Expansion of application range of products to address larger set of customers is another strategic initiative to enhance the business target which is likely to promote sales of AID products. For instance, in October 2019, Novo Nordisk received the U.S. Food and Drug Administration (FDA) approval for the expanded application of its Fiasp as insulin infusion pumps in adults with type 1 or type 2 diabetes as an improvement of glycemic control
- Rising diabetic population globally, many companies are investing to develop advanced technology. For instance, in February 2020, Becton, Dickinson and Company completed a clinical trial of its BD Libertas a wearable injectors
- Emerging technologies in medical device sector has been playing great role in rising the growth of AID. For instance, in March 2019, Abbott Laboratoriesand Novo Nordisk entered into non-exclusive partnership that will incorporate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system
- North America dominated the Automated Insulin Delivery Systems market with a revenue of USD 2.16 billion in 2019. Due to the higher prevalence of diabetes, and adoption of developed technologies the region is expected to rise during the forecast period
- Devices type segment held significant market share in 2019. The development of technologically advanced and cost-effective products is major factors driving the market growth
- Owing it to larger target population type 2 diabetes mellitus application segment accounted for highest market share in 2019; and is estimated to boom in forecast period. The expected surge in diabetic population due to pandemic lockdown restriction in various parts of the world and rising geriatric population are among major factors contributing to the expected market growth of this segment.
Inquiry Before Buying @ https://www.reportsanddata.com/inquiry-before-buying/3453
Asia Pacific is expected to lead the market growth over the coming years owing to rapid advancements in the healthcare sector in APAC countries such as India, China, and Japan. North America is anticipated to register the highest market growth over the forecast period attributed to the increasing availability of robust healthcare and clinical settings, legalization of medical marijuana, favorable reimbursement scenario, presence of key market players, and rapid technological advancements in the region.
The growing popularity of over-the-counter medications driving market growth
Growing incidence of acute and chronic diseases and lesser access to advanced medical facilities owing to low disposable income levels are driving the demand for over-the-counter medications. Availability of generic and low-cost alternatives to medical therapies are some other factors playing a major role in driving demand for over-the-counter medications.
Restriction on product launches and R&D activities to hamper the market growth
The imposition of strict government regulations and shortage of funds has put a halt on product launches and R&D activities and is expected to restrain market growth over the forecast period. In addition, the launch of expensive drugs and therapies and increasing regulations regarding safety and approvals are also hampering the market growth.
Competitive Landscape:
The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as R&D investments, license agreements, partnerships, mergers and acquisitions, collaborations, and joint ventures to gain a robust footing in the market.
Top Companies Profiled in the Report:
Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Biocon, Ypsomed, Wockhardt, Digital Medics, Abbott, Companion Medical, F. Hoffmann-La Roche, Ltd., BD, Animas LLC, Medtronic., Tandem Diabetes Care, Inc, Diabetes Care, BIGFOOT BIOMEDICAL, INC, DreaMed Diabetes, Ltd and WTWH Media LLC
Automated Insulin Delivery Systems Market Segmentation:
Product Type Outlook (Revenue in Million USD; 2017–2027)
- Devices
- Pens
- Reusable Insulin Pens
- Disposable Insulin Pens
- Insulin Pumps
- External/ Tethered Pumps
- Patch Pumps
- Implanted Insulin pump (IIP)
- Closed loop insulin pump (artificial pancreas)
- Pen Needles
- Standard Pen Needles
- Safety Pen Needles
- Insulin Syringes
- CGM
- Pens
- Software & Mobile App
- Others
Applications Outlook (Revenue in Million USD; 2017–2027)
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
End Use outlook (Revenue in Million USD; 2017–2027)
- Homecare
- Hospitals
- Clinics
- Others
Regional Outlook:
- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
- Latin America (Brazil, Rest of LATAM)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of the Middle East & Africa)
Frequently asked questions addressed in the report:
- What is the revenue growth rate of the global Automated Insulin Delivery Systems market over the forecast period?
- What are the major factors driving the growth of the Global Automated Insulin Delivery Systems Market?
- What are the key challenges impacting the global Automated Insulin Delivery Systems market growth?
- What are the outcomes of the SWOT Analysis and Porter’s Five Forces Analysis conducted in the report?
Request customization on the report @ https://www.reportsanddata.com/request-customization-form/3453
Thank you for reading our report. For more details please connect with us and our team will ensure the report is customized to meet all the needs of clients. The report also offers a comprehensive regional analysis and specific countries can be included in the report according to the requirements.
Explore Latest Trending Research Reports By Reports and Data:
Cerebrospinal Fluid (CSF) Management Market @ https://www.biospace.com/article/cerebrospinal-fluid-csf-management-market-is-expected-to-reach-usd-2-31-billion-in-2028-/
Viral Vector and Plasmid DNA Manufacturing Market @ https://www.biospace.com/article/viral-vector-and-plasmid-dna-manufacturing-market-revolutionary-trends-in-industry-growth-statistics-by-2028/
Single-Cell Sequencing Market @ https://www.biospace.com/article/single-cell-sequencing-market-size-worth-usd-3-230-6-million-by-2027-emergen-research-/
Next Generation Sequencing Market @ https://www.biospace.com/article/next-generation-sequencing-market-analysis-by-manufacturers-regions-types-and-applications-2027/
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
LinkedIn | Twitter | Blogs
Read the innovative blog at https://www.reportsanddata.com/blogs
Check out our upcoming research report at https://www.reportsanddata.com/upcoming-reports
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update: https://www.youtube.com/channel/UChLqKTFLm6sVBLEUjnadIhQ/videos